Disease Severity Underlies Advisory Committee Support For Kynamro
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Metabolic and Endocrinologic Advisory Committee votes 9 to 6 in favor of Genzyme’s mipomersen for homozygous familial hypercholesterolemia Oct. 18.